Literature DB >> 16782301

Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system.

Francis F Tukov1, Jane F Maddox, David E Amacher, Walter F Bobrowski, Robert A Roth, Patricia E Ganey.   

Abstract

Xenobiotic-inflammation interactions lead to hepatotoxicity in vivo. Selected xenobiotic agents (acetaminophen, APAP; chlorpromazine, CPZ; allyl alcohol, AlOH; monocrotaline, MCT) for which this occurs were evaluated for ability to elicit the release of Kupffer cell (KC)-derived inflammatory mediators and to modulate lipopolysaccharide (LPS)-stimulated release of these mediators. Using KCs and hepatocytes (HPCs) isolated from rat, KC/HPC cocultures were treated with either LPS, xenobiotic, vehicle or a combination. Six hours later, the release of inflammatory mediators was assessed. LPS alone caused a concentration-dependent increase in TNF-alpha release but had no significant effect on the release of PGE(2). APAP by itself did not alter release of TNF-alpha, PGE(2), IL-10, Gro/KC or IFN-gamma; however, in the presence of LPS, APAP enhanced LPS-induced TNF-alpha and Gro/KC release. APAP also attenuated LPS-induced increases in IL-10 and MCP-1. CPZ alone caused a concentration-dependent increase in TNF-alpha release, which was approximately additive in the presence of LPS. AlOH alone did not affect TNF-alpha release, but decreased TNF-alpha production in the presence of LPS. AlOH increased PGE(2) production, and this effect was potentiated in the presence of LPS. MCT by itself did not affect release of TNF-alpha but increased the response to LPS. Neither MCT, LPS, nor the combination affected production of PGE(2). These results demonstrate that KC/HPC cocultures can be used to evaluate interactions of xenobiotics with LPS. Furthermore, data from these studies qualitatively mirror reported data from whole animal studies, suggesting that this model could be useful for predicting aspects of xenobiotic-inflammation interactions in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782301     DOI: 10.1016/j.tiv.2006.04.005

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  24 in total

1.  Advancements in in vitro hepatic models: application for drug screening and therapeutics.

Authors:  Apeksha Damania; Era Jain; Ashok Kumar
Journal:  Hepatol Int       Date:  2013-12-05       Impact factor: 6.047

Review 2.  Application of biomaterials to advance induced pluripotent stem cell research and therapy.

Authors:  Zhixiang Tong; Aniruddh Solanki; Allison Hamilos; Oren Levy; Kendall Wen; Xiaolei Yin; Jeffrey M Karp
Journal:  EMBO J       Date:  2015-03-12       Impact factor: 11.598

Review 3.  Assembly of human organs from stem cells to study liver disease.

Authors:  Kan Handa; Kentaro Matsubara; Ken Fukumitsu; Jorge Guzman-Lepe; Alicia Watson; Alejandro Soto-Gutierrez
Journal:  Am J Pathol       Date:  2013-12-12       Impact factor: 4.307

4.  Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.

Authors:  Wei Zou; Sachin S Devi; Erica Sparkenbaugh; Husam S Younis; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2008-12-12       Impact factor: 4.849

5.  In vitro models for liver toxicity testing.

Authors:  Valerie Y Soldatow; Edward L Lecluyse; Linda G Griffith; Ivan Rusyn
Journal:  Toxicol Res (Camb)       Date:  2012-11-23       Impact factor: 3.524

Review 6.  Naturally-Derived Biomaterials for Tissue Engineering Applications.

Authors:  Matthew Brovold; Joana I Almeida; Iris Pla-Palacín; Pilar Sainz-Arnal; Natalia Sánchez-Romero; Jesus J Rivas; Helen Almeida; Pablo Royo Dachary; Trinidad Serrano-Aulló; Shay Soker; Pedro M Baptista
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

7.  Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells.

Authors:  George Kolios; Vassilis Valatas; Pinelopi Manousou; Costas Xidakis; George Notas; Elias Kouroumalis
Journal:  Mol Cell Biochem       Date:  2008-07-16       Impact factor: 3.396

8.  Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury.

Authors:  Wei Zou; Kevin M Beggs; Erica M Sparkenbaugh; A Daniel Jones; Husam S Younis; Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2009-07-28       Impact factor: 4.030

Review 9.  Liver tissue engineering in the evaluation of drug safety.

Authors:  Ajit Dash; Walker Inman; Keith Hoffmaster; Samantha Sevidal; Joan Kelly; R Scott Obach; Linda G Griffith; Steven R Tannenbaum
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-10       Impact factor: 4.481

10.  Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.

Authors:  Benjamin D Cosgrove; Bracken M King; Maya A Hasan; Leonidas G Alexopoulos; Paraskevi A Farazi; Bart S Hendriks; Linda G Griffith; Peter K Sorger; Bruce Tidor; Jinghai J Xu; Douglas A Lauffenburger
Journal:  Toxicol Appl Pharmacol       Date:  2009-04-09       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.